135 related articles for article (PubMed ID: 14713926)
21. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
[TBL] [Abstract][Full Text] [Related]
22. Carbapenems in serious infections: a risk-benefit assessment.
Norrby SR
Drug Saf; 2000 Mar; 22(3):191-4. PubMed ID: 10738843
[TBL] [Abstract][Full Text] [Related]
23. Imipenem in patients with immediate hypersensitivity to penicillins.
Romano A; Viola M; Guéant-Rodriguez RM; Gaeta F; Pettinato R; Guéant JL
N Engl J Med; 2006 Jun; 354(26):2835-7. PubMed ID: 16807429
[No Abstract] [Full Text] [Related]
24. Severe neutropenia in a patient treated with imipenem/cilastatin.
Fariñas MC; de Vega T; Garmendia J; González-Macías J
Eur J Clin Microbiol Infect Dis; 1993 Apr; 12(4):303-4. PubMed ID: 8513823
[No Abstract] [Full Text] [Related]
25. [Imipenem/cilastatin-induced acute thrombocytopenia].
Alegre Herrera S; Quirós Valera M; Rodríguez Fernández A
Med Clin (Barc); 2001 Jul; 117(5):197-8. PubMed ID: 11481089
[No Abstract] [Full Text] [Related]
26. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.
Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):85-8. PubMed ID: 1864280
[TBL] [Abstract][Full Text] [Related]
27. Worsening of myasthenia gravis on treatment with imipenem/cilastatin.
O'Riordan J; Javed M; Doherty C; Hutchinson M
J Neurol Neurosurg Psychiatry; 1994 Mar; 57(3):383. PubMed ID: 8158196
[No Abstract] [Full Text] [Related]
28. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.
Zanetti G; Harbarth SJ; Trampuz A; Ganeo M; Mosimann F; Chautemps R; Morel P; Lew D; Zimmerli W; Lange J; Glauser M
Int J Antimicrob Agents; 1999 Feb; 11(2):107-13. PubMed ID: 10221413
[TBL] [Abstract][Full Text] [Related]
29. Imipenem cilastatin sodium-associated thrombocytopenia in an older patient: A case report and literature review.
Qiao W; Chang C; Wang Q; Cao X; Zhang X
Int J Clin Pharmacol Ther; 2022 Aug; 60(8):358-363. PubMed ID: 35652550
[TBL] [Abstract][Full Text] [Related]
30. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery.
Kanellakopoulou K; Giamarellou H; Papadothomakos P; Tsipras H; Chloroyiannis J; Theakou R; Sfikakis P
Eur J Clin Microbiol Infect Dis; 1993 Jun; 12(6):449-53. PubMed ID: 8359165
[TBL] [Abstract][Full Text] [Related]
31. Cross-reactivity and Tolerability of Ertapenem in Patients With IgE-Mediated Hypersensitivity to β-Lactams.
Buonomo A; Pascolini L; Rizzi A; Aruanno A; Pecora V; Ricci AG; Mezzacappa S; Di Rienzo A; Centrone M; Nucera E; Schiavino D
J Investig Allergol Clin Immunol; 2016; 26(2):100-5. PubMed ID: 27164625
[TBL] [Abstract][Full Text] [Related]
32. Tolerability of meropenem in children with IgE-mediated hypersensitivity to penicillins.
Atanasković-Marković M; Gaeta F; Medjo B; Viola M; Nestorović B; Romano A
Allergy; 2008 Feb; 63(2):237-40. PubMed ID: 18186815
[TBL] [Abstract][Full Text] [Related]
33. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus.
Embil JM; Soto NE; Melnick DA
Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293
[TBL] [Abstract][Full Text] [Related]
34. Vertigo caused by intravenous imipenem/cilastatin.
Duque A; Altimiras J; García-Cases C; Vidal P
DICP; 1991 Sep; 25(9):1009. PubMed ID: 1949961
[No Abstract] [Full Text] [Related]
35. Prolonged continuous i.v. "desensitization" in Tienam hypersensitivity.
Confino-Cohen R; Goldberg A; Lang R
Allergy; 1997 Jun; 52(6):683-4. PubMed ID: 9226072
[No Abstract] [Full Text] [Related]
36. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
Geroulanos SJ
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
[TBL] [Abstract][Full Text] [Related]
37. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group.
Hamacher J; Vogel F; Lichey J; Kohl FV; Diwok K; Wendel H; Lode H
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():121-33. PubMed ID: 8543488
[TBL] [Abstract][Full Text] [Related]
38. Immune response in patients with intra-abdominal infections treated with carbapenems.
Brismar B; Eklund AE; Nord CE
Int J Clin Pharmacol Res; 1994; 14(3):111-4. PubMed ID: 7883388
[TBL] [Abstract][Full Text] [Related]
39. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
Basoli A; Meli EZ; Mazzocchi P; Speranza V
Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
[TBL] [Abstract][Full Text] [Related]
40. [Tolerance and safety of carbapenems: the use of meropenem].
Lizasoaín M; Noriega AR
Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():73-7. PubMed ID: 9410074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
